Wells Fargo analyst Edward Caso raised his price target for CACI to $250 from $225, noting that the company's initial 2020 outlook was well ahead of estimates for revenue, EBITDA and EPS. The analyst reiterates an Outperform rating with growth and margin promises now accelerating.

Truist raised the firm's price target on CACI to $450 from $410 and keeps a Buy rating on the shares after its Q3 earnings beat. The stock's discount valuation reflects the perception of CACI as a sub-par organic grower despite the best trailing-12-month book-to-bill in the group, the analyst tells investors in a research note. CACI is one of the most interesting capital deployment stories, with net leverage down to 2.0-times and a long history of M&A value creation, the firm added.

Consensus $20.31. Raises FY24 revenue view to $7.5B-$7.6B from $7.3B-$7.5B, consensus $7.4B.

Reports Q3 revenue $1.94B, consensus $1.86B. "CACI's outstanding performance reflects the continued successful execution of our strategy. We're winning and delivering in the marketplace with differentiated capabilities, exceptional business development, and program execution," said John Mengucci, CEO. "Our third quarter results were strong across the board, including double-digit organic growth, margin expansion, $3.5 billion of awards, and record backlog. Our performance enables us to again raise fiscal year 2024 revenue and earnings guidance. We remain confident in our ability to drive long-term growth, increase free cash flow, and generate value for our customers and our shareholders."